2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

Authors

  • Dinesh Khanna,

    1. University of Michigan, Ann Arbor
    Search for more papers by this author
    • Drs. Dinesh Khanna, FitzGerald, and Puja P. Khanna contributed equally to this work.

    • Dr. Dinesh Khanna has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Novartis and Ardea and (more than $10,000 each) from Takeda and Savient, and has served as a paid investment consultant for Guidepoint.

  • John D. Fitzgerald,

    1. University of California, Los Angeles
    Search for more papers by this author
    • Drs. Dinesh Khanna, FitzGerald, and Puja P. Khanna contributed equally to this work.

  • Puja P. Khanna,

    1. University of Michigan, Ann Arbor
    Search for more papers by this author
    • Drs. Dinesh Khanna, FitzGerald, and Puja P. Khanna contributed equally to this work.

    • Dr. Puja P. Khanna has received speaking fees (less than $10,000) from Novartis and (more than $10,000) from Takeda, and has served on the advisory board for Novartis.

  • Sangmee Bae,

    1. University of California, Los Angeles
    Search for more papers by this author
  • Manjit K. Singh,

    1. Rochester General Health System, Rochester, New York
    Search for more papers by this author
  • Tuhina Neogi,

    1. Boston University Medical Center, Boston, Massachusetts
    Search for more papers by this author
  • Michael H. Pillinger,

    1. VA Medical Center and New York University School of Medicine, New York
    Search for more papers by this author
    • Dr. Pillinger has received speaking fees and/or honoraria (less than $10,000 each) from the RA Investigator Network, NY Downtown Hospital, Winthrop Hospital, and Einstein College of Medicine.

  • Joan Merill,

    1. Oklahoma Medical Research Foundation, Oklahoma City
    Search for more papers by this author
  • Susan Lee,

    1. VA Healthcare System and University of California, San Diego
    Search for more papers by this author
  • Shraddha Prakash,

    1. University of California, Los Angeles
    Search for more papers by this author
  • Marian Kaldas,

    1. University of California, Los Angeles
    Search for more papers by this author
  • Maneesh Gogia,

    1. University of California, Los Angeles
    Search for more papers by this author
  • Fernando Perez-Ruiz,

    1. Hospital Universitario Cruces, Vizcaya, Spain
    Search for more papers by this author
    • Dr. Perez-Ruiz has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Novartis, Menarini, and Savient, and (more than $10,000) from Ardea.

  • Will Taylor,

    1. University of Otago, Wellington, New Zealand
    Search for more papers by this author
  • Frédéric Lioté,

    1. Université Paris Diderot, Sorbonne Paris Cité, and Hôpital Lariboisière, Paris, France
    Search for more papers by this author
    • Dr. Lioté has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Novartis Global, Novartis France, and Ipsen, and has served as a paid investment consultant for Gerson Lehrman Group.

  • Hyon Choi,

    1. Boston University Medical Center, Boston, Massachusetts
    Search for more papers by this author
    • Dr. Choi has served on the advisory boards (less than $10,000 each) for Takeda, URL, and Savient.

  • Jasvinder A. Singh,

    1. VA Medical Center and University of Alabama, Birmingham
    Search for more papers by this author
    • Dr. Singh has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Ardea, Savient, Allergan, and Novartis, and (more than $10,000) from Takeda, and has received investigator-initiated grants from Takeda and Savient.

  • Nicola Dalbeth,

    1. University of Auckland, Auckland, New Zealand
    Search for more papers by this author
    • Dr. Dalbeth has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Takeda, Ardea, and Novartis, has received research funding from Fonterra, and holds a patent from Fonterra for milk products for gout.

  • Sanford Kaplan,

    1. Oral and Maxillofacial Surgery, Beverly Hills, California
    Search for more papers by this author
  • Vandana Niyyar,

    1. Emory University, Atlanta, Georgia
    Search for more papers by this author
    • Dr. Niyyar has received honoraria (less than $10,000) from the American Society of Nephrology.

  • Danielle Jones,

    1. Emory University, Atlanta, Georgia
    Search for more papers by this author
  • Steven A. Yarows,

    1. IHA University of Michigan Health System, Chelsea
    Search for more papers by this author
  • Blake Roessler,

    1. University of Michigan, Ann Arbor
    Search for more papers by this author
  • Gail Kerr,

    1. Veterans Affairs Medical Center, Washington, DC
    Search for more papers by this author
    • Dr. Kerr has served as a study investigator (more than $10,000 each) for Savient and Nuon.

  • Charles King,

    1. North Mississippi Medical Center, Tupelo
    Search for more papers by this author
  • Gerald Levy,

    1. Southern California Permanente Medical Group, Downey
    Search for more papers by this author
  • Daniel E. Furst,

    1. University of California, Los Angeles
    Search for more papers by this author
  • N. Lawrence Edwards,

    1. University of Florida, Gainesville
    Search for more papers by this author
    • Dr. Edwards has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Savient, Takeda, Ardea, and Regeneron, and (more than $10,000) from Novartis, and has given expert testimony for Novartis.

  • Brian Mandell,

    1. Cleveland Clinic, Cleveland, Ohio
    Search for more papers by this author
    • Dr. Mandell has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Savient, Novartis, and Pfizer.

  • H. Ralph Schumacher,

    1. VA Medical Center and University of Pennsylvania, Philadelphia
    Search for more papers by this author
    • Dr. Schumacher has received consultant fees (less than $10,000 each) from Pfizer, Regeneron, West-Ward, and Ardea, and (more than $10,000) from Novartis.

  • Mark Robbins,

    1. Harvard Vanguard Medical Associates/Atrius Health, Somerville, Massachusetts
    Search for more papers by this author
  • Neil Wenger,

    1. University of California, Los Angeles
    Search for more papers by this author
  • Robert Terkeltaub

    Corresponding author
    1. VA Healthcare System and University of California, San Diego
    • VA Healthcare System/University of California, San Diego, 111K, 3350 La Jolla Village Drive, San Diego, CA 92161
    Search for more papers by this author
    • Dr. Terkeltaub has received consultant fees (less than $10,000 each) from Takeda, Savient, Ardea, BioCryst, URL, Regeneron, Pfizer, Metabolex, Nuon, Chugai, EnzymeRx, Ajanta, Anadys, Celgene, Isis, and Prescription Solutions, and (more than $10,000) from Novartis, has received grant support from the VA San Diego Healthcare System and the NIH, and has served as a paid investment consultant for Leerink Swann, Medacorp, and Guidepoint.


Ancillary